V-Go Insulin Delivery System
Simple All-Day-and-Night Insulin Delivery
Insulin delivery that’s worn like a patch! V-Go is designed to easily fit into your life and help you manage diabetes by combining all of your insulin needs into one simple patch-like device. No more insulin pens or syringes!
V-Go supplies insulin in two ways, similar to the way your body produces insulin:
- Provides a steady rate of background insulin over a 24-hour period
- Discreetly provides additional insulin at mealtimes by simply clicking a button
By using V-Go, you can live your life on the go without stopping to gather supplies or look for a private place to give yourself an injection.
This product may be covered by your insurance. Check now or call us at 888-344-3434.
Benefits of V-Go Insulin Delivery
Lowers A1C while using less insulin as compared to multiple daily injections (MDIs)1,2. With V-GO, there is no need to carry insulin pens, syringes. or vials. It is so discreet, nobody will know you’re using it — even at mealtimes. There is no batteries, tubes, or programming needed!
- Control blood glucose 24/7
- Apply like a patch once a day
- Easily comply with your treatment regimen
- Deliver 20, 30, or 40 units of insulin in one 24-hour period and on-demand bolus dosing in 2-unit increments
V-Go is reimbursed by many commercial insurances
- Only fast-acting insulin used — no need for long-acting insulin
- Many V-Go customers use insulin more efficiently, wasting less and using less, ultimately saving money
- No more copays for needles or syringes, saving even more money
Ready to Get Started with V-GO
Apply Today———- RELATED ARTICLES ———-
EHCS is an authorized distributor of V-Go Insulin Pump. We strive to provide you with quality products and multiple options.
References 1. Harrison HC, Everitt B, Nikkel C. Poster: The Impact of utilizing a novel insulin delivery device in patients with type 2 diabetes. Presented at ACCE. May 2017. 2. Lajara R, Nikkel C. Poster: Evaluating the effect of V-Go® therapy in sub-optimally controlled patients with diabetes: a retrospective cohort analysis on a large specialized diabetes system. Presented at ACCE. May 2015. 3. Lajara R, Nikkel C. Poster presented at: the International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting; May 2017; Boston, MA.
* Instructions for Patient Use
Important Risk Information If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Wearable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing.